C Reactive Protein (CRP)
Scl-70 (topo-I) (ATA)
There are a wide variety of autoantibodies associated with lupus. Some of the antibodies are helpful in diagnosing the illness, while others are more useful in detecting disease activity or potential complications. (Also see Autoimmune Diseases and Overview of Lupus)
Monoclonal antibody targeting BDCA2 ameliorates skin lesions in systemic lupus erythematosus (SLE). The data suggest that targeting plasmacytoid DCs may be beneficial for patients with SLE, especially those with cutaneous manifestations. PubMed, J Clin Invest, 2019 Mar 1;129(3):1359-1371.
Elevated serum autoantibodies against co–inhibitory PD-1 facilitate T cell proliferation and correlate with disease activity in new–onset systemic lupus erythematosus (SLE) patients. The current study indicates, for the first time, that the serum levels of co–inhibitor autoantibodies against PD-1 are elevated in new–onset SLE patients and are associated with disease activity in SLE. PubMed, Arthritis Res Ther, 2017 Mar 9;19(1):52.
Anti–CII antibody as a novel indicator to assess disease activity in systemic lupus erythematosus (SLE). Anti–dsDNA Abs and complement factors have been used as indicators of lupus activity and therefore, anti–CII Ab could be a novel indicator for monitoring activity of SLE. PubMed, Lupus.
Progression of subclinical atherosclerosis in systemic lupus erythematosus (SLE) versus rheumatoid arthritis: the impact of low disease activity. Plaque progression is accelerated in SLE regardless of disease activity, and is associated with antiphospholipid antibodies and the Systemic Coronary Risk Evaluation. PubMed, Rheumatology (Oxford), 08/08/2018.
Antiphospholipid antibodies and non-thrombotic manifestations of systemic lupus erythematosus. Presence of antiphospholipid syndrome or persistent antiphospholipid antibodies may be related to non–thrombotic and non–gestational systemic lupus erythematosus manifestations. PubMed, Lupus, 2018 Apr;27(4):665-669.
Prevalence, persistence and clinical correlations of classic and novel antiphospholipid antibodies in systemic lupus erythematosus (SLE). In this SLE cohort, the non–criteria aPL aD1 IgG and aPS-PT IgG performed differently. PubMed, Rheumatology (Oxford), 04/17/2018.
Antiphospholipid antibodies in patients with upper-extremity deep vein thrombosis (UEDVT). UEDVT could be the first clinical symptom of Antiphospholipid syndrome, and may be the first clinical manifestation of preceding the development of Systemic Lupus Erythematosus by several years. PubMed, Cent Eur J Immunol. (Also see Antiphospholipid Syndrome)
Anti-CRP antibodies in systemic lupus erythematosus. Anti-CRP autoantibodies, which are found in 35 to 40% of SLE patients, increase the cardiovascular risk by interacting with the monomeric (degraded) form of CRP. PubMed, Joint Bone Spine.
Functional anti-CD94/NKG2A and anti-CD94/NKG2C autoantibodies in patients with systemic lupus erythematosus (SLE). Anti-CD94/NKG2A and anti-CD94/NKG2C autoantibodies have the capacity to deplete certain NK cell subsets and interfere with particular NK cell function and may promote the pathogenesis of SLE. PubMed, Arthritis Rheumatol.
Topoisomerase I (topo-1) in Human Disease Pathogenesis and Treatments. In this review, we will summarize our current understandings on how TOP1 contributes to human diseases and how its activity is targeted for disease treatments. PubMed, Genomics Proteomics Bioinformatics, 2016 Jun;14(3):166-71.
Hashimoto thyroiditis (HT), anti–thyroid antibodies and systemic lupus erythematosus (SLE). There is a two–fold increased risk of HT in SLE patients, Anti–SM antibodies favor this association and also double antibody positivity. PubMed, Int J Rheum Dis, 05/25/2017. (Also see Hashimoto's Thyroiditis)
Anti–Sm is associated with the early poor outcome of lupus nephritis. Our data suggest that anti–Sm identified at kidney biopsy might have a predictive value for the early poor outcome of biopsy–proven lupus nephritis during the follow–up period. PubMed, Int J Rheum Dis, 04/29/2016. (Also see Symptoms and Complications of Lupus)
TOLL FREE HOTLINE, U.S. and Canada: 1-800-564-7099
Ask for our Free Info Packet by email or postal mail!
SCLERO.ORG is the world's leading nonprofit for trustworthy research, support, education and awareness for scleroderma and related illnesses.
We are a service of the nonprofit International Scleroderma Network (ISN), which is a 501(c)(3) U.S.-based public charitable foundation, established in 2002. Meet Our Team, or Volunteer. Donations may also be mailed to: